VMI
BCRX icon

VHCP Management II’s BioCryst Pharmaceuticals BCRX Stock Holding History

VHCP Management II’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,874,602
Closed -$8.24M – 22
2019
Q3 		$8.24M Hold
2,874,602
– – 3.14% 8
2019
Q2 		$10.9M Sell
2,874,602
-374,562
-12% -$2.25M 3.43% 9
2019
Q1 		$26.4M Hold
3,249,164
– – 7.74% 6
2018
Q4 		$26.2M Hold
3,249,164
– – 11.26% 4
2018
Q3 		$24.8M Buy
3,249,164
+784,923
+32% +$5.27M 6.62% 6
2018
Q2 		$14.1M Buy
2,464,241
+243,270
+11% +$1.34M 4.23% 8
2018
Q1 		$10.6M Sell
2,220,971
-261,148
-11% -$1.34M 2.56% 12
2017
Q4 		$12.2M Sell
2,482,119
-683,338
-22% -$3.31M 2.92% 10
2017
Q3 		$16.6M Buy
3,165,457
+690,290
+28% +$3.53M 4.58% 6
2017
Q2 		$13.8M Sell
2,475,167
-3,595,975
-59% -$21.9M 5.5% 7
2017
Q1 		$51M Hold
6,071,142
– – 20.87% 2
2016
Q4 		$38.4M Buy
6,071,142
+350,000
+6% +$1.82M 18.43% 2
2016
Q3 		$25.2M Hold
5,721,142
– – 12.95% 2
2016
Q2 		$16.2M Buy
5,721,142
+1,031,707
+22% +$3.2M 9.81% 4
2016
Q1 		$13.3M Buy
+4,689,435
New +$20.8M 8.73% 4

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VHCP Management II's BCRX Position: Q4 2019 in Review

VHCP Management II sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2019, closing a stake of 2,874,602 shares — an estimated $8.24M sold.

VHCP Management II first reported a position in BCRX in Q1 2016 and held it in 15 quarters. The position peaked at $51M in Q1 2017. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

  • VHCP Management II reported no remaining BioCryst Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • VHCP Management II sold 2,874,602 BioCryst Pharmaceuticals shares in Q4 2019, an estimated $8.24M.
  • VHCP Management II first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 15 quarters.
  • VHCP Management II's BioCryst Pharmaceuticals position peaked at $51M in Q1 2017.
  • 136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.